Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1[Inebilizumab][1] Inebilizumab (Inebilizumab)[1] Inebilizumab (Inebilizumab, Inebilizumab-cdon) 💬 [1] CD19 💬 [5] B cell receptor signaling pathway, Epstein-Barr virus infection, Hematopoietic cell lineage, PI3K-Akt signaling pathway, Primary immunodeficiency 💬[1] 300 💬
2INEBILIZUMAB[1] Inebilizumab (Inebilizumab)[1] Inebilizumab (Inebilizumab, Inebilizumab-cdon) 💬 [1] CD19 💬 [5] B cell receptor signaling pathway, Epstein-Barr virus infection, Hematopoietic cell lineage, PI3K-Akt signaling pathway, Primary immunodeficiency 💬[8] 11, 13, 46, 49, 51, 53, 95, 300 💬
3Inebilizumab + Rapid Steroid Tapering group[1] Inebilizumab (Inebilizumab)[1] Inebilizumab (Inebilizumab, Inebilizumab-cdon) 💬 [1] CD19 💬 [5] B cell receptor signaling pathway, Epstein-Barr virus infection, Hematopoietic cell lineage, PI3K-Akt signaling pathway, Primary immunodeficiency 💬[1] 13 💬
4Inebilizumab + Standard Steroid Tapering group[1] Inebilizumab (Inebilizumab)[1] Inebilizumab (Inebilizumab, Inebilizumab-cdon) 💬 [1] CD19 💬 [5] B cell receptor signaling pathway, Epstein-Barr virus infection, Hematopoietic cell lineage, PI3K-Akt signaling pathway, Primary immunodeficiency 💬[1] 13 💬
5Rapid-tapering glucocorticoids + Inebilizumab[1] Inebilizumab (Inebilizumab)[1] Inebilizumab (Inebilizumab, Inebilizumab-cdon) 💬 [1] CD19 💬 [5] B cell receptor signaling pathway, Epstein-Barr virus infection, Hematopoietic cell lineage, PI3K-Akt signaling pathway, Primary immunodeficiency 💬[1] 13 💬
6Slow-tapering glucocorticoids + Inebilizumab[1] Inebilizumab (Inebilizumab)[1] Inebilizumab (Inebilizumab, Inebilizumab-cdon) 💬 [1] CD19 💬 [5] B cell receptor signaling pathway, Epstein-Barr virus infection, Hematopoietic cell lineage, PI3K-Akt signaling pathway, Primary immunodeficiency 💬[1] 13 💬